Literature DB >> 9768533

Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus.

B T Cooper1, C S Neumann, M A Cox, T H Iqbal.   

Abstract

BACKGROUND: Because of the malignant potential of Barrett's oesophagus, an aim of treatment is to cause the columnar epithelium to regress. A logical approach is to decrease acid reflux which is an important aetiological factor in Barrett's oesophagus. Treatment with omeprazole 20-80 mg over 1-3 years has yielded conflicting but largely disappointing results. AIM: To determine if treatment of Barrett's oesophagus with omeprazole 20 mg daily for up to 6 years can cause regression of the Barrett's epithelium. PATIENTS AND METHODS: Forty-seven patients with Barrett's oesophagus were treated in an open prospective study. Nine patients were treated for 2 years, 12 for 3 years, 10 for 4 years, eight for 5 years and eight for 6 years. Patients were endoscoped at 1-2-year intervals and endoscoped at the end of the treatment period.
RESULTS: No significant shortening of the length of the Barrett's segment was seen during any treatment period, although omeprazole controlled reflux symptoms and was well tolerated. Macroscopic squamous islands appeared in 55% of patients, mostly in the first 2-3 years although in five patients they appeared later in treatment.
CONCLUSION: Treatment of Barrett's oesophagus with omeprazole 20 mg daily for periods of up to 6 years did not cause regression in the length of the Barrett's segment, but it did lead in over half of the patients to partial re-epithelialization in the form of squamous islands.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768533     DOI: 10.1046/j.1365-2036.1998.00389.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  12 in total

1.  Proton pump inhibitors for Barrett's oesophagus.

Authors:  G Triadafilopoulos
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

2.  Oesophageal pH monitoring in Barrett's oesophagus.

Authors:  C S Neumann; B T Cooper
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study.

Authors:  Mauro Rossi; Marco Barreca; Nicola de Bortoli; Cristina Renzi; Stefano Santi; Alessandro Gennai; Massimo Bellini; Francesco Costa; Massimo Conio; Santino Marchi
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

Review 4.  Barrett's oesophagus: the new endoscopic modalities have a future.

Authors:  J Deviere
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

5.  Carcinogenesis of Barrett's esophagus: a review of the clinical literature.

Authors:  Jiro Watari; Tadayuki Oshima; Hirokazu Fukui; Toshihiko Tomita; Hiroto Miwa
Journal:  Clin J Gastroenterol       Date:  2013-08-14

6.  Correlation of oesophageal acid exposure with Barrett's oesophagus length.

Authors:  R Fass; R W Hell; H S Garewal; P Martinez; G Pulliam; C Wendel; R E Sampliner
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 7.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

8.  The patterns of reflux can affect regression of non-dysplastic and low-grade dysplastic Barrett's esophagus after medical and surgical treatment: a prospective case-control study.

Authors:  Salvatore Tolone; Paolo Limongelli; Marco Romano; Alessandro Federico; Giovanni Docimo; Roberto Ruggiero; Luigi Brusciano; Gianmattia Del Genio; Ludovico Docimo
Journal:  Surg Endosc       Date:  2014-07-17       Impact factor: 4.584

Review 9.  The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review.

Authors:  Eugene Y Chang; Cynthia D Morris; Ann K Seltman; Robert W O'Rourke; Benjamin K Chan; John G Hunter; Blair A Jobe
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

Review 10.  Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure.

Authors:  Ronnie Fass
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.